Content - Euro Ewing 2012

Euro Ewing 2012 – International study for the treatment of newly diagnosed tumors of the Ewing sarcoma family

Ewing sarcoma is a rare cancer that can form in bone and soft tissue. It belongs to a group of tumours known as the Ewing Sarcoma Family of Tumours. The majority of Ewing sarcomas (around 85%) start in the bones, but they can also start in the soft tissues as well. It is the second most commonly diagnosed primary bone cancer in young people, after osteosarcoma. The Euro Ewing 2012 is a trial for the treatment of newly diagnosed Ewing Sarcoma.

Treatment for the Ewing’s sarcoma family of tumour usually includes a first phase called induction chemotherapy, followed by local control (surgery and/or radiotherapy) and a final phase of consolidation chemotherapy. The aim of the Euro Ewing 2012 trial is to compare two different chemotherapy regimens to determine which is more effective and/or has fewer side effects: the so-called VIDE chemotherapy that is the standard treatment used in Europe, and the VDC/IE chemotherapy that is used in the USA. If you participate in the trial, you may undergo treatment that includes the drugs vincristine, ifosfamide, doxorubicin and etoposide (VIDE), or you may receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide (VDC/IE) as an induction chemotherapy. A second aim of the trial is to test if a drug called zoledronic acid can improve treatment for Ewing sarcoma when added to the consolidation chemotherapy.

Study chair:

Dr. med. Attila Kollár, University Hospital Berne, +41 31 632 41 14

Locations for this trial:

Freiburgstrasse 8
3010 Bern
Kantonsspital St. Gallen
Rorschacher Strasse 95
0 9007 St. Gallen